Showing 1 to 12 of 79 results
DIPG Tumor Research: Insights from Lucía's Legacy
The donated tumor samples of 8-year-old Lucía García, who died of DIPG, a rare and aggressive brain cancer, have enabled breakthroughs in understanding its evasion of the immune system and potential therapeutic targets.
DIPG Tumor Research: Insights from Lucía's Legacy
The donated tumor samples of 8-year-old Lucía García, who died of DIPG, a rare and aggressive brain cancer, have enabled breakthroughs in understanding its evasion of the immune system and potential therapeutic targets.
Progress
12% Bias Score
CAR NK Cell Therapy Shows Promise in Autoimmune Disease Treatment
A new therapy using genetically engineered natural killer (NK) cells shows significant promise in treating autoimmune diseases like lupus, with early trials indicating high remission rates and minimal side effects compared to existing treatments, potentially offering a one-off cure for millions.
CAR NK Cell Therapy Shows Promise in Autoimmune Disease Treatment
A new therapy using genetically engineered natural killer (NK) cells shows significant promise in treating autoimmune diseases like lupus, with early trials indicating high remission rates and minimal side effects compared to existing treatments, potentially offering a one-off cure for millions.
Progress
48% Bias Score
Cancer Vaccine Shows Promise in Extending Survival for Pancreatic and Colorectal Cancer Patients
A small trial shows a new, mass-produced cancer vaccine may extend survival in pancreatic and colorectal cancer patients with KRAS gene mutations, offering potential benefits over personalized vaccines; however, larger trials are needed for confirmation.
Cancer Vaccine Shows Promise in Extending Survival for Pancreatic and Colorectal Cancer Patients
A small trial shows a new, mass-produced cancer vaccine may extend survival in pancreatic and colorectal cancer patients with KRAS gene mutations, offering potential benefits over personalized vaccines; however, larger trials are needed for confirmation.
Progress
40% Bias Score
Spanish Scientists Develop BO-112: A Breakthrough in Melanoma Treatment
Juana Santiago's metastatic melanoma, resistant to standard immunotherapy, went into remission after treatment with BO-112, a new drug developed by Spanish researchers at the CNIO, highlighting a breakthrough in melanoma treatment and the importance of clinical trials.
Spanish Scientists Develop BO-112: A Breakthrough in Melanoma Treatment
Juana Santiago's metastatic melanoma, resistant to standard immunotherapy, went into remission after treatment with BO-112, a new drug developed by Spanish researchers at the CNIO, highlighting a breakthrough in melanoma treatment and the importance of clinical trials.
Progress
44% Bias Score
New Glioblastoma Therapy Shows Promise in Clinical Trial
A New Jersey woman, Pamela Goldberger, 65, diagnosed with glioblastoma in 2023, is alive and healthy 2.5 years later after participating in a clinical trial for a new individualized dendritic cell therapy (DOC1021), showing promising results for this aggressive cancer.
New Glioblastoma Therapy Shows Promise in Clinical Trial
A New Jersey woman, Pamela Goldberger, 65, diagnosed with glioblastoma in 2023, is alive and healthy 2.5 years later after participating in a clinical trial for a new individualized dendritic cell therapy (DOC1021), showing promising results for this aggressive cancer.
Progress
40% Bias Score
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
Progress
52% Bias Score
Dutch Oncologists Develop Pioneering Immunotherapy Treatments, but Face Industry Opposition
Dutch oncologists have developed new immunotherapy treatments that cure more cancer patients with fewer drugs, but pharmaceutical companies are delaying wider access due to financial concerns.
Dutch Oncologists Develop Pioneering Immunotherapy Treatments, but Face Industry Opposition
Dutch oncologists have developed new immunotherapy treatments that cure more cancer patients with fewer drugs, but pharmaceutical companies are delaying wider access due to financial concerns.
Progress
48% Bias Score
Pancreatic Cancer Vaccine Shows Promise in Early Trials
A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...
Pancreatic Cancer Vaccine Shows Promise in Early Trials
A new pancreatic cancer vaccine, ELI-002 2P, showed promise in early trials, extending the survival time of pancreatic cancer patients to an average of 2 years and 5 months, compared to the current average of 1 year, by targeting KRAS-mutant cancer cells and improving vaccine delivery to lymph nodes...
Progress
40% Bias Score
Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations
An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.
Promising Results for Experimental Cancer Vaccine Targeting KRAS Mutations
An experimental cancer vaccine, ELI-002, designed to target KRAS mutations, shows promising results in a small trial with 25 patients, increasing the time before cancer recurrence in those with pancreatic cancer by an average of 15 months post-surgery and chemotherapy.
Progress
40% Bias Score
First Woman to Lead Top Biomedical Research Institute in Spain
Dr. Susana Puig, a dermatologist at Barcelona's Hospital Clínic, was appointed as the first female director of the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), leading to her stepping down from her clinical role to focus on research and translational science, impacting patient care.
First Woman to Lead Top Biomedical Research Institute in Spain
Dr. Susana Puig, a dermatologist at Barcelona's Hospital Clínic, was appointed as the first female director of the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), leading to her stepping down from her clinical role to focus on research and translational science, impacting patient care.
Progress
48% Bias Score
Non-Invasive Ultrasound Technique Improves Cancer Diagnosis and Treatment
Researchers at Georgia Tech and Emory University developed a novel ultrasound technique using FDA-approved microbubbles to label and track macrophages in real-time, offering a non-invasive method for improved cancer diagnosis, prognosis, and treatment with potential applications in drug delivery and...
Non-Invasive Ultrasound Technique Improves Cancer Diagnosis and Treatment
Researchers at Georgia Tech and Emory University developed a novel ultrasound technique using FDA-approved microbubbles to label and track macrophages in real-time, offering a non-invasive method for improved cancer diagnosis, prognosis, and treatment with potential applications in drug delivery and...
Progress
40% Bias Score
Virtual Sickness Triggers Immune Response: VR Study
A Swiss study used virtual reality to show that simply being near virtual sick people activated the immune systems of healthy participants, increasing innate lymphoid cell activity; researchers suggest VR may be a promising addition to other immune-boosting tools.
Virtual Sickness Triggers Immune Response: VR Study
A Swiss study used virtual reality to show that simply being near virtual sick people activated the immune systems of healthy participants, increasing innate lymphoid cell activity; researchers suggest VR may be a promising addition to other immune-boosting tools.
Progress
20% Bias Score
Showing 1 to 12 of 79 results